Harare, Zimbabwe- Zimbabwe has become one of the first ten African nations to launch the rollout of Lenacapavir, a breakthrough HIV prevention drug developed by Gilead Sciences. Unlike traditional Pre-Exposure Prophylaxis (PrEP), which requires a daily pill, Lenacapavir is administered via an injection every six months, offering what experts call "near-total protection" for high-risk groups.